The pharmaphorum ASCO 2018 daily bulletin | RSS News Feed

The pharmaphorum ASCO 2018 daily bulletin - Latest News

RSS Feed for this news: The pharmaphorum ASCO 2018 daily bulletin

The pharmaphorum ASCO 2018 daily bulletin

Bristol-Myers Squibb is hoping to revive its Opdivo cancer immunotherapy by combining it with an experimental agent from Nektar Therapeutics. But new early stage data from the cocktail presented at the American Society of Clinical Oncology ASCO 2018 has ... read more

Agenus to Present Clinical Data on Lead Programs at ASCO 2018

support a rapid path to BLA. "Our strategy is built on innovation and speed, critical elements for success in I-O. Our lead CTLA-4 and PD-1 are advancing rapidly in the clinic with more than 100 patients treated," said Garo Armen, PhD, Chairman and CEO of ... read more

NantOmics to Present Results of DESMOPAZ Study from French Sarcoma Group (FSG) at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting

during the sarcoma session at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting, an event bringing together 30,000 oncology professionals from June 1-5, 2018 at McCormick Place in Chicago, Illinois. NantWorks will be exhibiting at booth ... read more

Looking for another news?


ASCO 2018 – Tuesday 5th June: Tesaro developing checkpoint combo

Data released at ASCO 2018 is from TOPACIO, a phase 1/2 trial in ovarian cancer or triple negative breast cancer (TNBC). Following dose finding in phase 1, a Zejula (niraparib) pill was administered daily at a dose of 200 milligrams in combination with ... read more

Many breast cancer patients can safely skip chemo; here's why

Results were discussed Sunday at an American Society of Clinical Oncology conference in Chicago and published by the New England Journal of Medicine. Some study leaders consult for breast cancer drugmakers or for the company that makes the gene test. read more

CTCA at Southeastern First in Atlanta to Recruit Patients for ASCO's Groundbreaking TAPUR Clinical Trial

"We are excited to be one of ASCO's partner sites for the TAPUR Study. This is a progressive development for our patients and their loved ones." said Dr. Ricardo Alvarez, director of cancer research and breast medical oncologist at CTCA at Southeastern. read more

ASCO 2018: Genosco/Yuhan Announce Results from Phase 1/2 Study of Lazertinib (YH25448, GNS-1480), a 3rd-Generation EGFR-TKI, in Advanced NSCLC

at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting. Lazertinib (YH25448, GNS-1480), Genosco’s 3rd-generation EGFR-tyrosine kinase inhibitor (EGFR-TKI) candidate partnered for clinical development and commercialization with Yuhan ... read more

Vizient Commends the FDA on Its Recent Approval of the First Neulasta Biosimilar

IRVING, Texas--(BUSINESS WIRE)--Jun 5, 2018--Vizient today applauds the U.S. Food and Drug ... “Clarifying Our Understanding of Biosimilars in Oncology: Response to ASCO Statement.” Biosimilar competition strengthens the healthcare market via ... read more

Study: Herceptin treatment for breast cancer can be shorter

Dr. Bruce Johnson, president of the American Society of Clinical Oncology, said the study’s findings should ... In the United States, 266,000 new cases of invasive breast cancer are expected in 2018, and nearly 41,000 deaths. Globally, the most recent ... read more

NantOmics to Share Results of NantOmics Pharmacogenomics Test at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting

during the developmental therapeutics session at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting, an event bringing together 30,000 oncology professionals from June 1-5, 2018 at McCormick Place in Chicago, Illinois. NantWorks will be ... read more


FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us